Docetaxel Injection
Product Images NDC 46708-678

This is a description of Docetaxel Injection, an intravenous drug that comes in a 160mg/16mL vial. It is a cytotoxic agent that should only be used by prescription. The vial is sterile and ready to be added to an infusion solution after checking concentration. The package insert provides detailed instructions. The drug contains 10mg Docetaxel, 260 mg Polysorbate, 4mg Anhydrous Citic Acid, 23% Dehydrated Alcohol with Polyethylene Glycol 300 NF. It should be stored at 20-25°C and protected from light. Usual dosage is provided in the package insert. The product is manufactured by Alembic Pharmaceuticals, Inc. located in Bedminster, NJ.*

This is a description of Cetaxel Injection, USP, a cytotoxic agent that comes in a 20mg/2 mL (10 mg/mL) single-dose vial manufactured for Alembic Pharmaceuticals, Inc. The vial is for intravenous use only and any unused portion must be discarded. The solution is ready to add to an infusion and concentration should be checked prior to preparation. The package insert provides complete instructions. This medication should be stored at 20° to 25°C.*

This text appears to be a mix of various pharmaceutical information, including drug names, dosage instructions, and cautionary labels. It mentions an injection that is for intravenous use only and is a cytotoxic agent. It also provides dosage and storage instructions. However, the text is incomplete and contains lots of errors, making it difficult to determine the specific drug being described.*

Docetaxel Injection, USP is a cytotoxic agent medication available in the form of an 8 mL multiple-dose vial containing 80 mg/8 mL (10 mg/mL) of the drug. The medication is sterile and meant for intravenous use only. It is ready to add to an infusion solution after careful concentration checks. The medication should be stored at 20° to 25°C and protected from light. Each milliliter contains 10 mg Docetaxel, USP, 260 mg Polysorbate, 4 mg Anhydrous Citic Acid USP, 23% viv Dehydrated Alcohol USP, with Polyethylene Glycol 300 NF. Detailed instructions for preparation and dosage are available in the package insert. This medication is manufactured for Alembic Pharmaceuticals, based in Bedminster, NJ 07921, USA, and has a shelf life until January 2023.*

The given text seems to be a figure caption that shows a survival analysis for two treatment arms of a clinical trial. The data is presented using a Kaplan-Meier (K-M) curve and the x-axis shows the survival time (in months) while the y-axis shows the proportion of patients who survive. The two treatment arms are abbreviated as TPF and PF with sample sizes n=255 and n=246, respectively. The survival curve demonstrates that patients in the TPF arm had improved survival over the PF arm. However, without more information on the study design and patient characteristics, the clinical relevance of these findings cannot be determined.*

This is a survival curve comparison between Docetaxel 75 mg/m? and best supportive care. The x-axis represents the survival time in months, and the y-axis represents the cumulative probability of survival. The curve indicates that patients treated with Docetaxel had a higher probability of survival compared to those receiving best supportive care. The log-rank p-value for the comparison is 0.010.*

Figure 4 shows the TAX320 Survival K-M curves depicting a comparison between Docetaxel 75 mg/m2 and Vinorelbine or Ifosfamide control. The Logrankp value is 0.13. The graph shows the survival time in months.*

This is a survival probability graph, specifically a K-M (Kaplan-Meier) curve, from the TAX327 study. It shows the likelihood of survival over time for a certain population, measured in months. However, without additional information or context, it is not possible to determine the specific population or condition being studied.*

This is a figure showing the survival rate of patients with gastric cancer in a study called TAX325. The figure displays a Kaplan-Meier curve plot, where the survival time (in months) is plotted on the x-axis, and the survival rate (in percentages) is plotted on the y-axis. The curve starts at 100%, indicating that all patients were alive at the beginning of the study, and decreases over time as patients die. The study followed patients for up to 24 months.*